MedPage Today: Revisiting Neoadjuvant Hormones for ER+ Breast Cancer

Neoadjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer achieved response rates similar to those obtained with combination chemotherapy but with less toxicity, pooled data from 20 studies showed.

The findings have implications for a majority of women with newly diagnosed early breast cancer, most of which is ER-positive disease. Clinical experience in the adjuvant setting has shown that 50% to 75% of women with ER-positive breast cancer do not benefit from combination chemotherapy, said Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio.

Read the full story at MedPage Today

Share This Article!